Integral Investment Advisors Inc. Buys New Shares in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Integral Investment Advisors Inc. acquired a new position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) in the first quarter, HoldingsChannel.com reports. The firm acquired 4,000 shares of the exchange traded fund’s stock, valued at approximately $324,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Addison Advisors LLC increased its position in shares of SPDR S&P Biotech ETF by 27.4% during the 4th quarter. Addison Advisors LLC now owns 535 shares of the exchange traded fund’s stock valued at $48,000 after purchasing an additional 115 shares during the last quarter. Bourgeon Capital Management LLC increased its position in SPDR S&P Biotech ETF by 6.1% during the first quarter. Bourgeon Capital Management LLC now owns 2,822 shares of the exchange traded fund’s stock valued at $229,000 after acquiring an additional 163 shares during the last quarter. Wealth Alliance grew its stake in shares of SPDR S&P Biotech ETF by 4.4% during the fourth quarter. Wealth Alliance now owns 4,083 shares of the exchange traded fund’s stock valued at $368,000 after buying an additional 173 shares during the last quarter. Arlington Financial Advisors LLC increased its stake in SPDR S&P Biotech ETF by 0.8% in the 1st quarter. Arlington Financial Advisors LLC now owns 22,685 shares of the exchange traded fund’s stock worth $1,840,000 after buying an additional 181 shares during the period. Finally, RPg Family Wealth Advisory LLC raised its position in SPDR S&P Biotech ETF by 1.1% during the 4th quarter. RPg Family Wealth Advisory LLC now owns 17,904 shares of the exchange traded fund’s stock valued at $1,612,000 after purchasing an additional 200 shares in the last quarter.

SPDR S&P Biotech ETF Trading Up 0.0%

XBI opened at $84.27 on Tuesday. The stock has a fifty day moving average price of $78.40 and a 200-day moving average price of $86.52. SPDR S&P Biotech ETF has a 12 month low of $66.66 and a 12 month high of $105.47. The firm has a market cap of $4.99 billion, a price-to-earnings ratio of 11.47 and a beta of 0.85.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.